by Q1Web Admin | Apr 12, 2017 | Speaker Interview
2nd Annual Pharmaceutical Manufacturing Execution Systems Conference: Speaker Interview Brian DiVasta Principal Validation Engineer Genzyme Brian will be one of the distinguished speakers at the 2nd Annual Pharmaceutical Manufacturing Execution Systems Conference. ...
by Q1Web Admin | Apr 12, 2017 | News
Aiming to rectify noise-induced hearing loss, Frequency Therapeutics has begun financing for a small-molecule therapy which will help re-grow small hairs within the inner ear. This therapy is designed to mimic CRISPR and gene therapies to stimulate remaining cells...
by Q1Web Admin | Apr 12, 2017 | News
Neurocrine received approval from the FDA this week to begin commercialization of Ingrezza, currently the only FDA-approved treatment of tardive dyskinesia. The drug will help combat involuntary motions caused by the disease. As of the approval, Ingrezza is the first...
by Q1Web Admin | Apr 12, 2017 | News
After releasing drug circulation details last week, the FDA has approved Teva’s Austedo for commercialization. Austedo is meant to reduce the chorea associated with Huntington’s disease. Last week we reported that Teva had replaced molecules in Austedo for “heavy...
by Q1Web Admin | Apr 12, 2017 | News
ALung Technologies has announced its plans to begin US clinical trial testing after the FDA awarded the medical device firm Expedited Pathway Access for its artificial lung technology. The device, HemoLung Respiratory Assist System, was launched in 2013 outside of the...
